Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Condition: Hepatocellular Carcinoma Interventions: Drug: N Acetylcysteine; Drug: Dexamethasone; Other: Placebo Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions: Hepatocellular Carcinoma Non-resectable; Portal Vein Tumor Thrombus; Immune Checkpoint Inhibitors Interventions: Drug: Cadonilimab; Radiation: Stereotactic radiotherapy; Drug: Renvatinib Sponsor: First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions: Hepatocellular Carcinoma Non-resectable; Portal Vein Tumor Thrombus; Immune Checkpoint Inhibitors Interventions: Drug: Cadonilimab; Radiation: Stereotactic radiotherapy; Drug: Renvatinib Sponsor: First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Condition: Hepatocellular Carcinoma Interventions: Drug: N Acetylcysteine; Drug: Dexamethasone; Other: Placebo Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions: Hepatocellular Carcinoma Non-resectable; Portal Vein Tumor Thrombus; Immune Checkpoint Inhibitors Interventions: Drug: Cadonilimab; Radiation: Stereotactic radiotherapy; Drug: Renvatinib Sponsor: First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Condition: Hepatocellular Carcinoma Interventions: Drug: N Acetylcysteine; Drug: Dexamethasone; Other: Placebo Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions: Hepatocellular Carcinoma Non-resectable; Portal Vein Tumor Thrombus; Immune Checkpoint Inhibitors Interventions: Drug: Cadonilimab; Radiation: Stereotactic radiotherapy; Drug: Renvatinib Sponsor: First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Condition: Hepatocellular Carcinoma Interventions: Drug: N Acetylcysteine; Drug: Dexamethasone; Other: Placebo Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials